English (United States)

CHL became participating center of the ASCEND-5 study

reduce font Size enlarge font Size print content

ASCEND-5 is a phase 3, multicenter, randomized, open-label study of oral LDK378 (Certinib) versus standard chemotherapy in ALK Rearranged (ALK Positive) patients with non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib. The primary purpose of the study is to compare the antitumor activity of LDK378.

What is anaplastic lymphoma kinase-positive (ALK+)? When the ALK fusion gene is present in a lung tumor, it makes it positive for ALK. The ALK gene plays a key role in the pathogenesis of non-small-cell lung cancer. ALK positive patients with non-small cell lung cancer are initially sensitive to the ALK inhibitor crizotinib. The problem is that patients eventually become resistant to crizotinib which is limiting their therapeutic potential. The new investigational drug LDK378 represents an important treatment option for ALK-positive NSCLC patients who relapse after starting initial therapy with crizotinib.

The study aims to enroll 236 participants all over the world and is estimated to be completed by July 2017. Recently, the CHL was selected to participate to this trial as recruiting site with the participation of the CIEC. The recruitment is just starting now and offers patients the opportunity to receive this new treatment.
If you would like to have more information on this study, please visit our website under following link: www.luxclin.lu/Studies/Details/?c=STP1656HCD


Who should register?

Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.

Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.